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We performed a retrospective serologic survey of 583 
organ donors and 1043 transplant recipients for anti-
bodies to human immunodeficiency virus type 1 (HIV-
1). Two (0.34%) of the 583 donors and 18 (1.7%) of the 
1043 recipients had mV-I antibodies by enzyme im-
munoassay and by Western blot. Two of 5 seropositive 
recipients tested also had blood cultures positive for 
HIV-1. Seven (0.7%) of the 1043 transplant recipients 
had antibodies to HIV-I before transplantation; 2 of 
these had hemophilia A, and 5 had previous transfu-
sions. Eleven (1.3%) of 860 recipients followed for 45 
days or more seroconverted to HIV -1 a mean of 96 days 
after transplantation. Likely sources of mV-l infection 
for 3 of these 11 recipients included a seropositive organ 
donor in 1 patient and high-risk blood donors in 2 pa-
tients. A definite source of HIV-I infection was not 
found for the other 8 recipients, 3 of whom serocon-
verted to HIV -1 after institution of blood donor screen-
ing for HIV -1 antibodies. Seroconversion to HIV -1 was 
less common in kidney recipients than in liver, heart. or 
multiple-organ recipients (P<0.02). Nine (50%) of the 
18 mv -1 seropositive transplant recipients died a mean 
of 6 months after transplant surgery, and 9 (50%) are 
still alive a mean of 43 months after transplantation. 
AIDS-like illnesses occurred in 3 of the dead and 1 of 
the living patients and included pneumocystis pneu-
monia (3 cases), miliary tuberculosis (1 case), and recur-
rent cytomegalovirus infection (1 case). These data sug-
gest that the course of mv -1 infection is not more severe 
in transplant recipients receiving cyciosporine than in 
other hosts and that. despite screening of blood and 
organ donors, a small number of transplant recipients 
will become infected with HIV-1. 
The most important routes of transmission of the human 
immunodeficiency virus type 1 (HIV·l) are through sexual 
activity, transfusion of blood products, and transplacental pas-
sage of the virus from an infected mother to her child (1, 2). It 
is clear that exposure of transplant recipients to blood and 
blood products places them at risk for HIV -1 infection. In 
addition, donated organs may also transmit HIV·l infection as 
was recently reported by the Centers for Disease Control 
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(CDC)- for a patient who received a liver transplant in Pitts-
burgh (3). 
The pharmacologic immunosuppression used in transplant 
recipients predisposes them to many of the same opportunistic 
infections and tumors that afflict patients with the acquired 
immunodeficiency syndrome (4-6). Also, altered in vitro in· 
dices of immune function similar to those seen in patients with 
HIV -1 infection may be seen in allograft recipients (7, 8). Thus, 
the clinical diagnosis of AIDS may be difficult in the transplant 
setting. 
In order to establish the extent of infection and disease from 
HIV -1 in the transplant population and to assess the risk of 
acquiring infection from donated organs and donated blood, it 
is necessary to study a sizable population on whom adequate 
data are available. These data should include serum samples 
from donors, multiple serum samples from recipients both 
before and after transplantation, and clinical follow-up of ad-
equate duration to determine whether any HIV-l-associated 
disease occurs in the population. This study of 583 organ donors 
and 1043 organ recipients was undertaken to meet these needs. 
MATERIALS AND METHODS 
All patients underwent transplantation either at Presbyterian Uni· 
versity Hospital or Children's Hospital of Pittsburgh, except for 2, who 
received liver transplants at Baylor University Medical Center in 
Dallas, Texas, but who were later cared for in Pittsburgh. The trans-
plant recipients were immunosuppressed primarily with cyeioaporine 
and prednisone; the actual doses varied between transplant groups and 
over the time period studied. Before the introduction of eye!osporine 
monitoring, the eyeiosporine dosage was generally tspered from aD 
initial dose of 17.5 mglkg at surgery in accordance with clinical criteria 
such 88 the presence of rejection or the development of nephrotoxicity 
(9). Since mid-l983 eyclosporine dosage has been determined by ter-
geting the dosage required to maintain a blood level of about 800-1000 
ng/m! (Sandoz, RIA). Most patients were also treated with daily doaes 
of prednisone tspered to between 10 and 20 mg by 2-3 montha after 
surgery. Some patients also received either rabbit antithymoeyte glob-
ulin (RATG) or OKT3 mouse monoclonal antibodies either for pro-
phyluia or therapy of rejection. 
Since 1981 a senun bank has been maintained on transplant recipi· 
ents and donors for use in the clinical investigation of herpea~ 
infections associated with transplantation. Sera or plasma coUec 
between February 13. 1981 and April 30, 1986 and stored in this Kru~ 
bank were tested. All available serum samples from adult donort an 
• Abbreviations: CDC, Centers for Disease Control; RATG. rabbit 
antithymocyte globulin. 
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~ lut available serum or plasma sample from both adult and pediatric 
recipients who aurvived more than 75 days after transplantation were 
,aeened. These included sera from 583 adult donon and 1043 trans-
plant recipients, representing .2% of the 1394 donon acquired by the 
joCA1 donor procurement office and 61 % of the 1701 recipients given 
oreana during the time period studied. Sera were tested for antibody to 
tlIV·l by enzyme immunoassay using a commercial kit (LAV-EIA; 
Genetic Systems, Seattle, W A). Positive samples were retested in 
duPlicate by EIA. Repeat positives by EIA were confIrmed by the 
Weltern blot method Ummunoblot; Biorad, Richmond, CAl using a 
JCC)ring system based on the presence and density of banda correspond-
inC to the molecular weight of HIV-l proteins, p18. p24. p32. gp41 .... 3. 
p55. p65, gp120 (10, 11). A negative band was assigned a score of 0, a 
weakly reactive band 1. a moderately reactive band 2. a strongly reactive 
band 3, and a very strongly reactive band 4. A summed score of i!:3 was 
dermed as a poaitive immunoblot, a score of 2 as equivocal and a score 
of Sl 0 a negative immunoblot. Selected specimens were also tested 
by a Western blot procedure in a commercial laboratory (Biotech 
Research Laboratories, Rockville, MD). A transplant recipient was 
considered to have HIV·l antibodies if the EIA and either of the 
Western blot tests were positive on a serum sample. and if these 
antibodies. once detected. were penistently found in subsequent serum 
samples. In addition to the sera screened.. the following sera were also 
teated for HIV -1 antibodies: (1) multiple, including pretransplant. sera 
from recipients positive on EIA screening; and (2) the last available 
eerum from any recipient who had received an organ from an EIA or 
Western blot positive donor or who had received an organ from a donor 
who had donated organs to another recipient who became HIV-l 
positive after transplantation. 
HIV·l isolation was performed by a modification of the method of 
Levy (12. 13). Briefly, 8XI0' mononuclear lymphocytes from a patient 
were cocultivated in 10 ml of RPM I medium containing 20% fetal 
bovine serum and 10% interleukin 2 with 3xIO' phytohemagglutinin· 
stimulated cells from a normal donor_ Thereafter, 3XIO' mitogen· 
ltimulated normal cells were added to the culture twice a week for a 
period of • weeks. Culture fluids were harvested every. dsys and tested 
for the presence of HIV -1 by the antigen capture assay (Cellular 
Producta; Buffalo. NY). 
Demographic and clinical data were collected on the seropositive 
recipients and included age at transplantation. sex, type of organ 
transplant, number of transfusions during the admission for transplant 
surgery, the use of additional RATG or OKT3, survival, and the 
occurrence of infections or tumon. T-helper and T-suppressor cell 
counts or ratios were noted when available. Since many patients were 
dead at the time of the study and othen no longer resided near 
Pittsburgh, membership in a high-risk group for HIV-l infection could 
often only be evaluated from medical records. An "AIDS· like illness" 
in a transplant recipient was dermed as any opportunistic infection or 
tumor that fulfilled the CDC criteria for AIDS with the exception of 
invuive candida infections, which are common in liver transplant 
recipients. Seropositive donors were evaluated for age, sex, mode of 
death. known membenhip in a high-risk group for HIV-l infection, 
and the number of transfusions received before organ donation. 
Proportions were analyzed by a two-tailed Fisher's exact test. A p. 
value of :s0.05 '110 considered significant. 
RESULTS 
Population studied. Characteristic8 of the recipient popula-
tion are shown in Table 1. Of the 1043 recipients, 868 (83%) 
were adults. Of the 175 pediatric recipients, 144 (82%) received 
liver transplants. Recipient sera included samples from 171 
heart recipients, 292 liver recipients, 550 kidney recipients, and 
30 multiple-organ recipients of whom the majority were heart-
lung recipients. The duration of serologic follow-up ranged from 
o to 1775 days. However. 860 (82%) of the 1043 transplant 
TABLE 1. Transplant recipients studied for HIV infection 
Transplant 
Any follow·up >46 nays follow-up 
type <:18" <18" Total No. <:18" <18" Total No. patientl patientl 
Heart 165 6 171 163 0 163 
Renal 529 21 550 .20 18 .38 
Liver 148 144 292 119 114 233 
Mult. organ 26 4 30 25 1 26 
Total 868 175 1043 727 133 860 
• Age of recipient (years). 
recipients had greater than 45 days of serologic follow-up 
(mean= 352 days) and represented 51 % of the total transplant 
population during the study period. 
An important issue in this study was the route of transmis-
sion of the virus. Testing of blood products for HIV -1 antibodies 
was introduced at our central blood bank on March 31. 1985. 
The sera collected and studied included sera from 640 organ 
recipients who underwent transplantation before 3/31/85 and 
sera from 403 organ recipients who underwent transplantation 
after 3/31/85. Ninety-three percent (592/640) of the patients 
who received organs before this date. but only 67% (268/403) 
of the patients who received organs after this date, had more 
than 45 days of follow-up (P<O.OOI). 
Pretransplant HIV-J positive recipients. Seven (0.7%) of 1043 
patients had positive EIA and Western blot tests for HIV-l 
before transplantation (Table 2); all remained positive for HIV-
1 antibodies after transplantation. Two of the 7 patients were 
hemophiliacs, and the other 5 were not recognized as belonging 
to any high-risk group but had received transfusions prior to 
nationwide blood screening, generally at other centers, before 
transplant surgery. None had an illness associated with HIV-1 
infection at the time of transplantation. 
The prevalence of pretransplant HIV -1 positivity in recipi-
ents less than 18 years of age, 2.3% (4/175), was significantly 
higher than in adults (0.3%, 3/868 P<O.05). Two positive 
pediatric liver transplant recipients were less than 3 years of 
age (Table 2). Serum was not available from the mother of 
patient 5, but serum obtained from the natural mother of 
patient 2 was negative for HIV -1 antibodies. Patient 5 was 
positive for HIV antibodies at 51h months old when she was 
evaluated for transplantation. She had received numerous blood 
transfusions since birth. It was unlikely that her HIV-l anti-
body positivity was due to passive transfer of maternal anti-
bodies since the last serum available from her was still positive 
5 months after transplantation and 10 months after birth. 
Three of the 7 recipients who were HIV -1 positive prior to 
transplantation died at 4, 6, and 9 months after transplantation. 
Four others are living and well at 26, 38, 43, and 46 months 
after transplantation, although 1 (patient 3; Table 2) has lost 
his transplanted kidney and is not receiving immunosuppres-
sion. Of the 3 patients who died, only 1 (patient 7; Table 2) 
developed an AIDS-like illness. This was a previously reported 
48-year-old hemophiliac who received a liver transplant for 
cirrhosis secondary to chronic active hepatitis (14). At the time 
oftransplantation, he had a T-helper(f-suppres80r ratio ofO.3. 
Ten weeks after transplantation, he developed. pneumocystis 
pneumonia that responded slowly to treatment with sulfameth-
oJ.azoie/trimethoprim and then pentamadine. He subsequently 
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developed renal failure, hepatic artery thrombosis, ascending 
cholangitis, candida pyelonephritis, and terminal pneumonia 
due to Pseudomonas aeruginosa. The other deaths were due to 
probable drug toxicity (patient 1) and pulmonary aspiration 
(patient 5). 
Posttranspiant HIV·1 positive recipients. Eleven transplant 
recipients who were initially seronegative for HIV·l developed 
HIV -1 antibody after transplantation (Table 3). Seven had 1 
or more subsequent sera positive for HIV·l antibodies, and 4 
were positive for HIV·l antibodies only on the last available 
serum. The mean time ±SD of seroconversion after transplan· 
tation, computed as the 1st day a postoperative sample was 
positive by EIA and/or Western blot, was 96±49 days after 
transplantation. Only the organ donor of patient 4 (Table 3) 
was positive for HIV·l antibodies. The other 10 recipients had 
15 separate organ donors, including 3 recipients with 2 donors 
and 1 recipient with 3 donors. Sera from 11 of these 15 donors 
were negative for antibodies by EIA; sera were not available 
from the other 4 donors. All seroconverters received blood 
transfusions at the time of transplantation, and most also 
received transfusions after transplantation but prior to sero· 
conversion. Two patients (patients 5 and 6; Table 3) were 
discovered to have received blood from a high·risk donor by 
the local blood bank's "look·back" program. Three other recipe 
TABLE 2. Transplant recipients who were positive for HIV 
antibodies before transplantation" 
Patient ~=n Age/ie'S DOT Riak ATG/ FlU Vital AIDS·like fKtor OKT3 (montha) statu. illness" 
1. Liver 42/F 11/82 Trans No 6 Dead No 
2. Liver 3/F 7/83 Trans No 46 Alive No 
3. Renal 131M 10/83 Trans No 43 Alive No 
4. Renal 29/F 3/84 Trans No 38 Alive No 
5. Liver O.5/F 2/85 Trans Yea 9 Dead No 
6. Liver 151M 3/85 Hemoph No 26 Alive No 
7. Liver 48IM 10/85 Hemoph Yes 4 Dead PCP 
• DOT: date of transplant (month/year); ATG: antithymocyte glob· 
ulin; OKT3: OKT3 mouse monoclonal antibodies; F /U: follow·up; PCP: 
Pneumocystis carinii pneumonia; Trans: blood transfusions; Hemoph: 
hemophilia A. 
• These patients had illnesses, with the exception of candida infec· 
tions. that fulfllied the CDC criteria for the acquired immunodeficiency 
syndrome. 
ients (patients 9, 10, and 11; Table 3), however, received organ 
transplants after local screening of blood products for HIV-l 
antibodies went into effect. Sera from the organ donora of 
patients 10 and 11 were negative for HIV·l antibodies. Donor 
serum was not available from patient 9 for her 1st transplan· 
tation at another center. She was later brought to Pittsburgh 
for evaluation and retransplantation. The first HIV-l positive 
sample from her was taken 1 day before her retransplant surgery 
and showed antibodies against multiple HIV-l antigens on 
Western blot. Patient 10 was a 2-year·old boy who received 206 
blood units during his hospital admission for transplantation. 
He developed a positive EIA 87 days after transplantation and 
15 days later both a positive EIA and Western blot (p24, p55, 
gpI20). Patient 11 received several units of blood in another 
hospital in the year preceding transplantation. He then received 
3 blood units at the time of transplantation and also 20 units 
between 4 and 5 months after transplantation. He developed a 
positive EIA to HIV·1 145 days after transplantation and had 
both a positive EIA and Western blot (p24, p55) 2 weeks later. 
Rates of seroconversion possibly due to blood were calculated 
for patients who did not have a positive organ donor, who were 
not seropositive for HIV-l before transplantation, and who bad 
at least 45 days of follow·up. The overall rate of seroconveraion 
was 10/852 or 1.2%. This included 3 (2.3%) of 129 children and 
7 (1.0%) of 723 adults (P=NS). The seroconveraion rates in 
the different transplant populations were 0.2% (1/436) for 
kidney recipients, 1.8% (3/162) for heart recipients, and 2.6% 
(6/228) for liver recipients. The rate of seroconversion observed 
in kidney recipients (0.2%) is significantly less than the rate of 
seroconversion (2.2%, 9/416) in all other recipients (P<0.02) 
and is consistent with their exposure to fewer blood products 
at transplantation. However, the rate of seroconversion in 
patients who underwent transplantation before screening of 
blood donora for HIV-I antibodies was 1.2% (7/585) and did 
not differ significantly from the rate of 1.1 % (3/267) in patienta 
who underwent transplantation after screening of blood donors. 
Six of the 11 transplant recipients who seroconverted to 
HIV·l died at 4, 4, 5, 5, 6, and 14 months after transplantation, 
and 5 are still living at 40, 42, 45, 51, and 56 months after 
transplantation. Three of the 11 patients have had illnesses 
possibly associated with HIV·l infection, and they are de-
scribed below. 
A 42-year-old heart transplant recipient (patient 1; Table 3) 
TABLE 3. Transplant recipients who seroconverted to HIV after transplantation" 
Patient Age/~Dp Ol'pll DOT Time of Blood ATG/ FlU Vital AIDS·like illneu type conversion" (unita)' OKT3 (months) statua 
1. 42IM H 8/82 43-49 56 Yes 14 Dead PCP, listeria, 
toxoplasmo-
sis 
2. 341M H 9/82 75-189 130 No 56 Alive None 
3. 43/F L 2/83 55-90 143 No 51 Alive None 
4. 53IM H 2/83 28-44 67 No 4 Dead None 
5. 5IM L 8/83 14-103 16 Yes 45 Alive None 
6. 31M L 11/83 90-105 414 No 42 Alive None 
7. 32/F L 1/84 19-47 72 No 40 Alive Recurrent CMV 
8. 45IM H 2/84 24-46 34 No 5 Dead None 
9. 47/F L 6/85 0-148 299 Yes 5 Dead None 
10. 21M L 9/85 74-87 206 Yes 4 Dead None 
11. 381M R 4/86 135-145 3 Yes 6 Dead PCP/TB 
---" H: beart; L: liver; R: renal; CMV: cytomegalovirus infection; TB: tuberculosis; for other abbreviations .. Table 2. 
• Day after transplantation of 1aat negative lerology-day of first poaitive aerolOC)' . 
• Includes total units of red blood cella, fresh (rozen plaama. platelets, and cryoprecipitate during admillion (or transplantation. 
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did well after transplantation except that he developed mod-
erate rejection that required treatment with steroids and ATG. 
He seroconverted to HIV -1 49 days after transplantation but 
did not become ill at that time. Eleven months after transplan-
tation he developed chronic fatigue, and 2 months later he 
developed listeria meningitis and subsequently fatal pneumo-
cystis pneumonia. Focal involvement of his heart with toxo-
plasm08is was also found at autopsy. 
Patient 7 (Table 3), a 32-year-old liver recipient, had a brief 
febrile illness 2 weeks after surgery for which no cause was 
found. She became HIV -1 positive 47 days after transplantation 
but was clinically well until 3 years after her transplant surgery 
when she developed recurrent episodes of esophagitis due to 
berpes simplex virus and cytomegalovirus. 
Patient 11 (Table 3) was a 38-year-old man who developed 
pneumocystis pneumonia 3 months after renal transplantation. 
One month later he returned to the hospital with new diffuse 
chest infiltrates initially thought to be due to recurrent pneu-
mocystis infection but later diagnosed as miliary tuberculosis 
on open lung biopsy. It is interesting that his seroconversion 
to HIV -1 positivity at 145 days after transplantation postdated 
these 2 opportunistic infections. He died of sepsis 6 months 
after transplantation. 
Four patients in this series died without evidence of illnesses 
associated with HIV -1 infection. Two (patients 4 and 8; Table 
3) died of rejection shortly after heart transplantation. The 
other deaths were in liver recipients. A 47-year-old woman with 
primary biliary cirrhosis (patient 9; Table 3) developed rejection 
requiring OKT3 therapy after hepatic transplantation and also 
had stenosis of the hepatic artery with an associated bacterial 
liver abscess. She eventually required retransplantation, and 
she died 1 day later of technical complications of surgery. The 
other (patient 10; Table 3) was a 2-year-old boy with biliary 
atresia whose postoperative course was complicated by severe 
rejection, thrombosis of the hepatic artery with an associated 
biliary leak, disseminated candida infection, and respiratory 
distress syndrome. Postmortem 4 months after transplantation 
disclosed thrombosis of the hepatic artery, multiple bile-stained 
intraperitoneal abscesses, and pseudomonas pneumonia. 
EIA-positive but Western-blot negative recipients. Five recip-
ients not reported above each had only a single serum positive 
by EIA but negative by Western blot. Three patients died 
shortly after the date of the positive EIA sample, and 2 are still 
living, but follow-up sera are not available. 
Patients with transient appearance of HIV-J antibodies. 
Three patients who had positive Western blot tests are not 
listed in Tables 2 or 3 because later serum samples did not 
contain HIV -I antibodies. In 1 case a likely explanation for the 
transient appearance of HIV -1 antibodies was found. This 
patient underwent liver transplantation for chronic active hep-
atitis and cirrhosis secondary to hepatitis-B infection. A pre-
transplant serum sample was negative for HIV -1 antibodies. A 
serum sample taken 22 days after transplantation was positive 
for HIV-1 antibodies by EIA and Western blot on multiple 
lanes, but a subsequent sample, taken 318 days after transplan-
tation, was negative. He had received massive quantities (300 
001) of hepatitis-B immune globulin in the peritransplant period 
as part of an experimental protocol to protect his hepatic 
allograft against reinfection with hepatitis-B virus. The tran-
sient appearance of HIV -1 antibody was felt to be due to passive 
transfusions of antibody as has been previously described (15). 
In the other 2 patients the source of the transient Western 
blot positivity was not apparent. A man who received a heart 
transplant was HIV -1 seronegative before transplantation. 
Serum samples taken 16 and 37 days after transplantation were 
positive for HIV-1 antibodies by EIA; the 37-day sample was 
also positive for antibodies to p24 and p55 on Western blot 
testing. Two subsequent samples obtained 135 and 275 days 
after transplantation were negative. The other patient was a 3-
year-old boy who had a single serum taken 113 days after liver 
transplantation that was positive by Western blot (p18, p24, 
p55, p65) but negative for EIA. The serum was tested by 
Western blot because the EIA result was in the high negative 
range. A sample taken 28 days later was negative by both EIA 
and Western blot. The patient died of multiple bacterial infec-
tions 165 days after transplantation. Both patients had received 
organ transplants after institution of HIV -I blood screening, 
and a review of their records did not reveal any plausible source 
of passively transfused antibodies. 
Donors positive lor HIV-l. Two (0.34%) of 583 donors were 
found to be positive for HIV -I antibodies. One donor was a 
single 28-year-old man who died of head injuries from a motor 
vehicle accident; the other donor was a 32-year-old married 
man who committed suicide. Neither donor received blood 
products before organ harvesting, and neither was known to be 
a member of a high-risk group for HIV-1 infection. One patient 
in our cohort received a heart from the 1st donor and serocon-
verted to HIV -I 44 days after transplantation. This donor also 
donated kidneys to 2 recipients at another hospital, but infor-
mation on their HIV -1 status is not available. Two patients 
received kidneys from the other donor; neither had HIV-l 
antibodies detectable on their last available serum samples 
obtained 32 and 945 days after transplant surgery. 
Western blot patterns and viral cultures. All 20 individuals 
(18 recipients and 2 donors) identified as HIV -1 positive by 
Western blot in this study had antibodies against at least 2 of 
the major proteins of HIV -1. One donor and 1 recipient (patient 
11; Table 3) had antibodies only against p24 and p55 on a 
single serum sample. All other 18 individuals had antibodies 
against p24 and at least 2 other HIV -I antigens, including 
gp41-43 and/or gp120, on 1 or more sera. HIV-1 viral cultures 
were performed on 5 of the surviving HIV-1 seropositive pa-
tients, and 2 were positive (patients 3 and 6; Table 3). 
Clinical outcomes. Nine (50%) of the 18 patients who had 
HIV -1 infection either before or after transplantation (Tables 
2 and 3) are still living a mean of 43 months after transplan-
tation; 9 died a mean of 6 months after transplant surgery. 
Three of the dead and 1 of the living patients have had AIDS-
like illnesses as described above. 
Infections with herpesviruses, particularly cytomegalovirus, 
are primarily reported as complications of AIDS (16). Only 1 
of the 18 patients reported here had a documented tissue 
invasive cytomegalovirus infection (patient 7, Table 3). Three 
others had febrile CMV syndromes in the early posttransplant 
period, which resolved. It is possible that some febrile syn-
dromes were missed because of the retrospective nature of the 
study. No patient had a disseminated herpes simplex or herpes 
zoster infection or a lymphoproliferative syndrome either re-
lated or unrelated to Epstein-Barr virus infection. 
Seven of the 18 HIV-1 infected patients received either 
antithymocyte globulin or OKT3 for the treatment or propby-
laxis of rejection, and 6 (86%) died during the follow-up period. 
By contrast, only 3 (27%) of 11 patients who did not get RA TO 
or OKT3 died (P=O.05). Three (75%) of the 4 patients with 
AIDS-like illnesses received OKT3 or ATG compared with .. 
(29%) of 14 patients without AIDS-like illnesses (P=NS). 
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The Jarr:est organ subgroup of HIV·I seropositive patients in 
this selia coosists of 11 liver transplant recipients. of whom 6 
ERR~D are still alive a mean of.2 months (range. 26-51 months) 
after transplantation. The duration of HIV-l infection is 
known for the 6 who were seroconvertera and is equivalent to 
the interTal of follow-up after transplantation. The duration of 
HIV·I infection for the 5 patients who were seropositive for 
HIV·I before transplantation is unknown but is at least as long 
as the follow·up after transplantation. It is clear from these 
data that the combination of HIV -I infection and cyclosporine 
and prednisone immunosuppression is compatible with years 
of survival in a substantial subgroup of transplant recipients. 
DISCUSSION 
A number of studies report HIV·I infection in smaller co· 
horts of transplant recipients and discuss the role of donor 
transmission (17-24). This present study represents the largest 
investigation of HIV-l infection in kidney. liver. heart, and 
multiple organ transplant recipients and donors to date. It is 
apparent that transplanted organs may transmit HIV -I infec· 
tion much like transfused blood products. In a report from 
Berlin. West Germany. 5 kidney allograft recipients who re-
ceived orgaos from 3 intravenous drug users seroconverted to 
HIV-I shortly after transplantation (19). Although HIV-I sere 
ologies were not available on the donors. the transmission of 
the virus infection for 4 recipients of 2 pairs of kidneys makes 
the organs a likely source. A few other cases of apparent 
transmission via the donor organ have been reported in recip-
ients of kidneys from a hemophiliac and a male homosexual 
(l8. 21). Recently, an organ donor whose test for HIV-l anti· 
bodies became negative after multiple blood transfusions was 
found to transmit the infection to both a liver and a kidney 
recipient (3). The liver recipient received his transplant at this 
center after the conclusion of this study. In our survey of 583 
donors,2 (0.34%) were found to be positive for HIV-l antibod-
ies. This is quite similar to the 0.38% rate reported by Kerman 
in Houston kidney donors but much higher than the rate of 
0.04% reported in blood donors (17, 25). Although we docu-
mented 1 transmission of HIV-1 by a donated heart, lack of 
adequate follow-up and the small number of cases precluded a 
full evaluation of the risk of transmission of HIV-l infection 
by organ donation. However, because donated organs may 
transmit HIV -1 infection. all organ donors should be tested for 
HIV -I antibodies, and their organs not used for transplantation 
if the screening test is positive. Testing should ideally be 
initiated early in the donor assessment process and performed 
on a serum sample taken before blood transfusion (3). 
There is some evidence that immunosuppressed persons may 
handle HIV-l infection poorly. Anderson et al. studied 10 
cancer patients who had received traosfusions from a single 
HN-I positive donor. Nine of the 10 seroconverted, and 6 of 
these 9 developed ARC or AIDS-like illnesses a mean of 286 
days after infusion of the contaminated blood products (26). 
Other cases of fatal disease consistent with AIDS have been 
described in HIV-1 infected transplant recipients (18,20, 22, 
23). In male homosexual, drug-abuser, and hemophiliac popu-
lations,. it haa been found that 8-34 % of individuals develop 
AIDS in a 3-year interval after detection of a positive antibody 
test (27). Using a mathematical model, Liu has estimated a 
mean incubation period for transfusion-related AIDS of •. 5 
years (28). Our experience suggests that at least half of trans-
plant recipients with HIV -1 infection may survive in good 
health for 3-4 years after transplantation even with cycl08por-
ine immunosuppression. The 11 liver transplant recipients, who 
formed the largest subgroup. had an overall survival of 55% 
with a mean of P~ years of follow-up in surviving patients. 
This compares favorably with an actuarial survival of 64% at 
3 years and 62% at " years in all liver transplant recipients on 
cyclosporine at this center from 1980 to 1987.3 
Four patients had illnesses that fulfllied the CDC criteria for 
AIDS. In 2 cases the only AIDS-like illness was pneumocystis 
pneumonia, a not-infrequent complication in organ transplant 
recipients without HIV-I infection (29). Another patient de-
veloped pneumocystis pneumonia and miliary tuberculosis, but 
both illnesses occurred before seroconversion to HIV -I. Con-
versely, several patients in this series had invasive candidiasis 
or severe bacterial infections but were not judged to have an 
AIDS-like illness, as these infections are common in transplant 
recipients (9, 30). Notably absent in the series are cases of 
Kaposi's sarcoma, cryptosporidiosis, and disseminated Myco-
bacterium-alJium-intraceUulore infection, which are rare in 
traosplant recipients but common in patients with AIDS (31, 
32). 
These data suggest that it is premature to make HIV-l 
infection an absolute contraindication to life-saving transplant 
procedures such as heart or liver transplantation on the pre-
sumptive basis of a poor outcome. The data available on out-
comes in HIV-l infected kidney-transplant recipients are lim-
ited, but it may be advisable to defer renal transplantation (and 
other nonlifesaving types of transplantation) in HIV -I infected 
individuals until more information related to the outcome iJ 
available. Even the performance of heart and liver traosplan-
tation in infected individuals should be undertaken only after 
careful evaluation. In particular. the presence of AIDS (and 
possibly AIDS-related complex) in a transplant candidate 
should be a contraindication to transplantation at the present 
time since it is a sign of established immunosuppression, and 
would likely entail a high risk of serious infection in the early 
posttransplant period. 
An interesting finding in the study was the significantly 
poorer outcome in transplant recipients who had HIV-l infec· 
tion and received either ATG or OKT3 treatment for rejection. 
Although most of the deaths in the group who received these 
anti-T-cell globulins for rejection did not appear to be directly 
related to HIV -I infection, this finding suggesta that careful 
consideration be given before administering these treatmentl 
to traosplant recipients with HIV-I infection. The timing oC 
HIV-I seroconversion in the recipients infected after tran'-
plantstion is similar to or slightly longer than the incubatioll 
period in well-studied cases of primary HIV -I infection (18,33. 
34). This suggests that these infections were probably tranJ" 
mitted around the time of transplantation or shortly thereafter. 
Although the source of infection was apparent only for 2 
patients who were hemophiliacs and 3 patienta who either 
received organs from seropositive organ donors or blood froID 
high-risk blood donors, it is likely that most if not all of t.bI 
other patients acquired their infection from blood prod~ 
This is suggested by the significantly lower rate of HIV' 
• Stanl TE. Iwatauki S, Esquivel CO, et al. Experience in 1000 = 
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infection in kidney recipients who receive smaller quantities of 
blood than do heart and liver recipients. Furthermore, none of 
the the seroconverters were known to belong to a high-risk 
,roup for HIV-l infection. 
Seven patients in the study had positive HIV -1 antibodies 
before transplantation. Although the hemophiliac patients were 
known to have HIV -1 antibodies before transplantation, the 
presence of the infection was not suspected in the other pa-
tients. The prevalence of HIV -1 seropositivity before trans-
plantation was higher in patients who are leBS than 18 years of 
age than in adults. This (mding might indicate a greater sus-
ceptibility of children to infection with HIV -1 but might also 
only be due to a greater exposure of patients with liver disease, 
who make up the majority of the pediatric population, to 
infected blood products. We could not document a significant 
reduction in IiIV -1 seroconversions in patients who underwent 
transplantation after the institution of routine blood screening 
for HIV -1 antibodies. Three patients seroconverted after blood 
screening was instituted, and 2 of the 3 also had organ donors 
with negative HIV-l antibody tests. The source of HIV-l 
infection in these 3 patients is not known. In the 2-year-old 
child. however, a false negative blood test on 1 of his many 
blood donors seems most likely. Such false negative tests have 
been described (35), and although they are thought to be 
uncommon their actual frequency is unknown. 
A major issue in this study is whether the positive serologic 
tests reported here indicate true HIV -1 infection. Transplant 
recipients are exposed to foreign antigens from organ donation, 
blood transfusion, and exogenous infections, any of which 
might result in the formation of cro88reacting antibodies. The 
detection of 3 patients with transiently positive Western blot 
tests shows the difficulties inherent in studying such a popu-
lation and suggests that caution should be exercised in inter-
preting isolated positive serologies for HIV -1 in transplant 
recipients. However, 14 of the 18 HIV-l positive recipients had 
more than 1 positive Western blot result. Few false positive 
Western blots have been described except for those with an 
isolated p24 band or occasionally for those with isolated p24 
and p55 bands (J 1,36). Since most of our Western blots were 
repeatedly positive at multiple bands, it is likely that they 
indicate true infection. Another indication that we are not 
dealing with false positives is the isolation of the virus from 
the blood of 2 of 5 samples from surviving patients. 
It is possible that cyclosporine may have modified the course 
of these patients' HIV-l infection in some way. One group of 
researchers has reported that cyclosporine prevents both the 
binding of HIV -1 to T cells and viral replication in T cells in 
vitro (37). These results need to be corumned. but immunologic 
surveillance of infected patients who are receiving cyclosporine 
may provide insight into this possibility. 
Current screening procedures for blood and organ donors 
should reduce the number of new HIV -1 infections in organ 
transplant recipients. NonetheleBS, we detected 3 HIV-1 aero-
conversions that occurred despite screening of blood products, 
and thus it is likely that occasional HIV -1 infections will 
continue to occur after transplantation. Increasing numbers of 
HIV -1 infected patients are also likely to present as candidates 
for transplantation. Only systematic screening and follow-up 
of transplant candidates and recipients for HIV -I infection will 
allow the careful prospective evaluation that is necessary to 
formulate rational decisions regarding their transplantability 
and long-term management. 
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RISK FACTORS FOR SENSITIZATION BY BLOOD 
TRANSFUSIONS 
COMPARISON OF THE UW jMADISON AND UCjSAN FRANCISCO DONOR-SPECIFIC TRANSFUSION EXPERIENCE1 
WILLIAM J_ BURLINGHAM,2 ROBERT STRATTA. BETH MASON, DAVID LORENTZEN, JAN FEYZI, 
HANS W. SOLLINGER, AND FOLKERT O. BELZER 
Department of Surgery. University of Wiscon.sin Hospital and Clinics. Madison. Wisconsin 53191 
We have tested the predictive model for risk of sensi-
tization by donor-specific transfusions developed at the 
University of California, San Francisco for its applica-
bility to the DST experience at UW /Madison. Patient 
sample sizes between the two groups were similar 
(n=249 for UW/Madison, n=281 for UCSF) and the two 
groups of patients had similar compositions in terms of 
I This work was supported by NIH Grant No. DK31774 and by 
University of Wisconsin Surgical Auociates. 
2 Address correspondence to: William J. Burlingham. Department of 
Surgery. University of Wisconsin Hospital and Clinics. 600 Highland 
Avenue. Madison. WI 53792. 
mean age, ABO type, baseline panel-reactive antibodY, 
and pregnancy rate. The two groups differed in tha~D" 
UW /Madison group had a higher percentage of OJ ... 
diabetic patients, previously transplanted patientt, ali II 
o haplotype-matched (2 HLA-mismatched related ali. 
unrelated) recipients. In addition, all the UW/Mad;:Jt 
patients received azathioprine (AZA) whereas onl~tfeIK 
the UCSF group was given AZA. Despite th~ d:i 01 
ences, application of the UCSF model for prediCtJOJl a. 
sensitization by DST gave remarkably similar resut:.,. 
our patient population, with pregnancy, prior ~"iD" 
plant, baseline PRA, and HLA antigen sharin'.· ... 
similar odds ratios and P values. However, when lelll 
